Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients

Blood

Volumn 91, Issue 1, 1998, Pages 295-300

  Hoffbrand, A Victor ^a   Al Refaie, Faris ^b   Davis, Bernard ^b   Siritanakatkul, Noppadol ^b   Jackson, Beverly F A ^b   Cochrane, John ^b   Prescott, Emma ^b   Wonke, Beatrix ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFERIPRONE; FERRITIN; IRON;

ADULT; AGRANULOCYTOSIS; ARTHROPATHY; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REFRACTORY ANEMIA; URINARY EXCRETION;

EID: 0031985039     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.1.295.295_295_300     Document Type: Article

References (27)

1. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Laulicht M, Fenton LA, Scheuer PJ, Kibbler CC, Allwood CA, Brown D, Thomas HC: Iron state and hepatic disease in patients with thalassemia major, treated with long term subcutaneous desferrioxamine. J Clin Pathol 40:1353, 1987
2. Wolfe L, Olivieri N, Sallan D, Steven Colan RN, Rose V, Propper R, Freedman MH, Nathan DG: Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 312:1602, 1985
3. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, Hilson AJW: High incidence of cardiomyopathy in beta thalassemia patients receiving regular transfusion and iron chelation: Reversal by intensified chelation. Acta Haematol 84:113, 1990
4. Al-Refaie FN, Hoffbrand AV: Oral iron chelation therapy. Recent Adv Haematol 7:185, 1993
5. Al-Refaie FN, Hoffbrand AV: Oral iron chelation therapy: The L1 experience. Baillieres Clin Haematol 7:941, 1994
6. Hoffbrand AV: Oral iron chelation. Semin Hematol 33:1, 1996
7. Olivieri NF, Brittenham GM: Iron chelation therapy and treatment of thalassemia. Blood 3:739, 1997
8. Barry M, Sherlock S: Measurement of liver iron concentration in needle biopsy specimen. Lancet 1:100, 1971
9. Al-Refaie FN, Wonke B, Hoffbrand AV: Deferiprone-associated myelotoxicity. Eur J Haematol 53:298, 1994
10. Al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ: Efficacy and possible adverse effects of the oral iron chelator 1,2dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 3:593, 1992
11. Agarwal MB, Gupta SS, Vismanathan C, Vasandani D, Ramanathan J, Desai N, Puniyani RR, Chhablani T: Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 82:460, 1992
12. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L: Effective chelation of iron in β thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxyprid-4-one. BMJ 295:1509, 1987
13. Kontoghiorghes GJ, Aldouri MA, Sheppard LN, Hoffbrand AV: 1,2-dimethyl-3-hydroxypyrid-4-one, an orally active chelator for the treatment of transfusional iron overload. Lancet 1:1294, 1987
14. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, Nortey P: Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). Br J Haematol 76:295, 1990
15. Olivieri NF, Koren G, Hermann G, Bentur Y, Chung D, Klein J, St Louis P, Freedman MH, McClelland RA, Templeton DM: Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 336:1275, 1990
16. Töndury P, Wagner HP, Kontoghiorghes GJ: Update of long term clinical trials with L1 in beta thalassaemia major patients in Bern, Switzerland. Drugs Today 28:115, 1992 (suppl A)
17. Olivieri NF, Brittenham GM, Armstrong SAM, Basran RK, Daneman R, Daneman N, Ivanchko RM, Talbot AL, Koren G: First prospective randomized trial of the chelators deferiprone (L1) and deferoxamine. Blood 86:249a, 1995 (abstr, suppl 1)
18. Olivieri NF, for The Iron Chelation Research Group (Toronto, Canada): Randomised trial of deferiprone (L1) and deferoxamine (DFO) in thalassemia major. Blood 88:651a, 1996 (abstr, suppl 1)
19. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Lin PP, Templeton DM, Koren G: Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 332:918, 1995
20. Bassett ML, Halliday JW, Powell LW: Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 6:24, 1986
21. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331:567, 1994
22. Cao A, Gabutti V, Masera G, Modell B, Sirchia G, Vullo C, Wonke B: Management Protocol for the treatment of thalassemia patients. Cooleys Anemia Foundation, New York, 1992
23. Al-Refaie FN, Shepphard LN, Nortey P, Wonke B, Hoffbrand AV: Pharmacokinetics of the oral iron chelator deferiprone (L1), in patients with iron overload. Br J Haematol 89:403, 1995
24. Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ: Long term trial with the oral iron chelator 1-2-dimethyl-3-hydroxypyrid-4-one (L1): Clinical observations: Br J Haematol 76:301, 1990
25. Cunningham JM, Hunter AB, Hoffbrand AV, Al-Refaie FN, Veys P, Wilkes S, Francis GE: Differential toxicity of α-ketohydroxypyridine iron chelators and desferrioxamine to human hemopoietic precursors in vitro. Eur J Haematol 52:176, 1994
26. Al'Refaie FN, Wonke B, Hoffbrand AV: The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system. Br J Haematol 87:196, 1994
27. Araujo A, Kosaryan M, MacDowell A, Wickens D, Puri S, Wonke B, Hoffbrand AV: A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload. Br J Haematol 93:835, 1996